Schizophrenia and the immune system: Pathophysiology, prevention, and treatment

American Journal of Health-System Pharmacy

Volumn 69, Issue 9, 2012, Pages 757-766

  Richard, Michelle D ^a   Brahm, Nancy C ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

Anakinra; Antibodies; Antipsychotic agents; Atlizumab; Azathioprine; Celecoxib; Enzyme inhibitors; Immune system; Immunosuppressive agents; Mechanism of action; Pediatrics; Pregnancy; Schizophrenia; Site of action

Indexed keywords

AZATHIOPRINE; BIOLOGICAL MARKER; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE ANTIBODY; GAMMA INTERFERON; IMMUNOMODULATING AGENT; NEUROLEPTIC AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ENVIRONMENTAL FACTOR; GENETIC DISORDER; HUMAN; IMMUNE SYSTEM; IMMUNOPATHOGENESIS; NEUROANATOMY; PATHOPHYSIOLOGY; PATIENT COUNSELING; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SYSTEMATIC REVIEW;

EID: 84860320284     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp110271     Document Type: Review

References (121)

1. National Institute of Mental Health. What is schizophrenia? www.nimh.nih.gov/health/publications/schizophrenia/what-is-schizophrenia.shtml (accessed 2011 Jul 20).
2. Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, "just the facts" 4. Clinical features and conceptualization. Schizophr Res. 2009; 110:1-23.
3. Eaton WW, Byrne M, Ewald H et al. Association of schizophrenia and autoimmune diseases: linkage of Danish national registers. Am J Psychiatry. 2006; 163:521-8. (Pubitemid 44469397)
4. Leucht S, Burkard T, Henderson J et al. Physical illness and schizophrenia: a review of the literature. Acta Psychiatr Scand. 2007; 116:317-33. (Pubitemid 47537428)
5. Gorwood P, Pouchot J, Vinceneux P et al. Rheumatoid arthritis and schizophrenia: a negative association at a dimensional level. Schizophr Res. 2004; 66:21-9. (Pubitemid 38030341)
6. Wright P, Sham PC, Gilvarry CM et al. Autoimmune diseases in the pedigrees of schizophrenic and control subjects. Schizophr Res. 1996; 20:261-7. (Pubitemid 26232970)
7. Himelhoch S, McCarthy JF, Ganoczy D et al. Understanding associations between serious mental illness and HIV among patients in the VA health system. Psychiatr Serv. 2007; 58:1165-72. (Pubitemid 47507955)
8. Rogers DP, Goldsmith CA. Treatment of schizophrenia in the 21st century: beyond the neurotransmitter hypothesis. Expert Rev Neurother. 2009; 9:47-54.
9. Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry. 1987; 44:660-9. (Pubitemid 17099795)
10. Jarskog LF, Miyamoto S, Lieberman JA. Schizophrenia: new pathological insights and therapies. Annu Rev Med. 2007; 58:49-61. (Pubitemid 46706500)
11. Rǎdulescu A. A multi-etiology model of systemic degeneration in schizophrenia. J Theor Biol. 2009; 259:269-79.
12. Vuillermot S, Weber L, Feldon J et al. A longitudinal examination of the neurodevelopmental impact of prenatal immune activation in mice reveals primary defects in dopaminergic development relevant to schizophrenia. J Neurosci. 2010; 30:1270-87.
13. Keshavan MS, Tandon R, Boutros NN et al. Schizophrenia, "just the facts": what we know in 2008. Part 3: neurobiology. Schizophr Res. 2008; 106:89-107.
14. Steen RG, Mull C, McClure R et al. Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. Br J Psychiatry. 2006; 188:510-8. (Pubitemid 43844097)
15. Yolken RH, Torrey EF. Viruses, schizophrenia, and bipolar disorder. Clin Microbiol Rev. 1995; 8:131-45.
16. Tandon R, Keshavan MS, Nasrallah HA. Schizophrenia, "just the facts": what we know in 2008. 2. Epidemiology and etiology. Schizophr Res. 2008; 102:1-18.
17. Brown JS Jr. Association of increased prenatal estrogen with risk factors for schizophrenia. Schizophr Bull. 2011; 37:966-9.
18. Holick MF. Vitamin D deficiency. N Engl J Med. 2007; 357:266-81.
19. Sø rensen HJ, Mortensen EL, Reinisch JM et al. Association between prenatal exposure to bacterial infection and risk of schizophrenia. Schizophr Bull. 2009; 35:631-7.
20. Dalman C, Allebeck P, Gunnell D et al. Infections in the CNS during childhood and the risk of subsequent psychotic illness: a cohort study of more than one million Swedish subjects. Am J Psychiatry. 2008; 165:59-65. (Pubitemid 351704553)
21. Hammond CJ, Hobbs JA. Parvovirus B19 infection of brain: possible role of gender in determining mental illness and autoimmune thyroid disorders. Med Hypotheses. 2007; 69:113-6. (Pubitemid 46686946)
22. Messias EL, Chen CY, Eaton WW. Epidemiology of schizophrenia: review of findings and myths. Psychiatr Clin North Am. 2007; 30:323-38. (Pubitemid 47299146)
23. Parham P. The immune system. Chaps. 1 and 3. 2nd ed. New York: Garland Science, Taylor & Francis Group; 2005.
24. Goldsmith CA, Rogers DP. The case for autoimmunity in the etiology of schizophrenia. Pharmacotherapy. 2008; 28:730-41. (Pubitemid 351975377)
25. Strous RD, Shoenfeld Y. Schizophrenia, autoimmunity and immune system dysregulation: a comprehensive model updated and revisited. J Autoimmun. 2006; 27:71-80. (Pubitemid 44528264)
26. Hall PD, Weimert NA. Function and evaluation of the immune system. In: DiPiro JT, Talbert RL, Yee GC et al., eds. Pharmacotherapy: a pathophysiologic approach. 7th ed. New York: McGraw-Hill Medical; 2008:1417-23.
27. Leonard BE. Is there an immunologic basis for schizophrenia? Expert Rev Clin Immunol. 2005; 1:103-12.
28. Selten JP, Frissen A, Lensvelt-Mulders G et al. Schizophrenia and 1957 pandemic of influenza: meta-analysis. Schizophr Bull. 2010; 36:219-28.
29. Brown AS, Hooton J, Schaefer CA et al. Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring. Am J Psychiatry. 2004; 161:889-95. (Pubitemid 38625343)
30. Fruntes V, Limosin F. Schizophrenia and viral infection during neurodevelopment: a pathogenesis model? Med Sci Monit. 2008; 14:RA71-7. (Pubitemid 351929699)
31. Brown AS, Begg MD, Gravenstein S et al. Serologic evidence of prenatal influenza in the etiology of schizophrenia. Arch Gen Psychiatry. 2004; 61:774-80. (Pubitemid 39031117)
32. Babulas V, Factor-Litvak P, Goetz R et al. Prenatal exposure to maternal genital and reproductive infections and adult schizophrenia. Am J Psychiatry. 2006; 163:927-9. (Pubitemid 44464544)
33. Brown AS, Derkits EJ. Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am J Psychiatry. 2010;167:261-80.
34. Brown AS, Schaefer CA, Quesenberry CP Jr et al. Maternal exposure to toxoplasmosis and risk of schizophrenia in adult offspring. Am J Psychiatry. 2005; 162:767-73. (Pubitemid 40489141)
35. Mortensen PB, Nørgaard- Pedersen B, Waltoft BL et al. Toxoplasma gondii as a risk factor for early-onset schizophrenia: analysis of filter paper blood samples obtained at birth. Biol Psychiatry. 2007; 61:688-93.
36. Xiao J, Buka SL, Cannon TD et al. Serological pattern consistent with infection with type I Toxoplasma gondii in mothers and risk of psychosis among adult offspring. Microbes Infect. 2009; 11:1011-8.
37. Buka SL, Tsuang MT, Torrey EF et al. Maternal infections and subsequent psychosis among offspring. Arch Gen Psychiatry. 2001; 58:1032-7. (Pubitemid 33051828)
38. Brown AS, Schaefer CA, Quesenberry CP Jr et al. No evidence of relation between maternal exposure to herpes simplex virus type 2 and risk of schizophrenia? Am J Psychiatry. 2006; 163:2178-80. (Pubitemid 46114240)
39. Buka SL, Cannon TD, Torrey EF et al. Maternal exposure to herpes simplex virus and risk of psychosis among adult offspring. Biol Psychiatry. 2008; 63:809-15. (Pubitemid 351400765)
40. Brown AS, Cohen P, Harkavy-Friedman J et al. A.E. Bennett Research Award. Prenatal rubella, premorbid abnormalities, and adult schizophrenia. Biol Psychiatry. 2001; 49:473-86.
41. Brown AS, Cohen P, Greenwald S et al. Nonaffective psychosis after prenatal exposure to rubella. Am J Psychiatry. 2000; 157:438-43. (Pubitemid 30145931)
42. Klyushnik TP, Turkova IL, Danilovskaya EV et al. Correlation between levels of autoantibodies to nerve growth factor and the clinical features of schizophrenia in children. Neurosci Behav Physiol. 2000; 30:119-21. (Pubitemid 30410155)
43. Dietert RR, Zelikoff JT. Pediatric immune dysfunction and health risks following early-life immune insult. Curr Pediatr Rev. 2009; 5:36-51.
44. Debnath M, Chaudhuri TK. The role of HLA-G in cytokine homeostasis during early pregnancy complicated with maternal infections: a novel etiopathological approach to the neurodevelopmental understanding of schizophrenia. Med Hypotheses. 2006; 66:286-93. (Pubitemid 41773902)
45. Dammann O, Leviton A. Maternal intrauterine infection, cytokines, and brain damage in the preterm newborn. Pediatr Res. 1997; 42:1-8. (Pubitemid 27276750)
46. Brown AS, Hooton J, Schaefer CA et al. Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring. Am J Psychiatry. 2004; 161:889-95. (Pubitemid 38625343)
47. Sallie R. Replicative homeostasis II: influence of polymerase fidelity on RNA virus quasispecies biology: implications for immune recognition, viral autoimmunity and other "virus receptor" diseases. Virol J. 2005; 2:70.
48. McAllister AK, van de Water J. Breaking boundaries in neural-immune interactions. Neuron. 2009; 64:9-12.
49. Nunes SO, Matsuo T, Kaminami MS et al. An autoimmune or an inflammatory process in patients with schizophrenia, schizoaffective disorder, and in their biological relatives. Schizophr Res. 2006; 84:180-2.
50. Teixeira AL, Reis HJ, Nicolato R et al. Increased serum levels of CCL11/eotaxin in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2008; 32:710-4. (Pubitemid 351312370)
51. Potvin S, Stip E, Sepehry AA et al. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry. 2008; 63:801-8. (Pubitemid 351410515)
52. Avgustin B, Wraber B, Tavcar R. Increased Th1 and Th2 immune reactivity with relative Th2 dominance in patients with acute exacerbation of schizophrenia. Croat Med J. 2005; 46:268-74. (Pubitemid 40686507)
53. Riedel M, Spellmann I, Schwarz MJ et al. Decreased T cellular immune response in schizophrenic patients. J Psychiat Res. 2007; 41:3-7. (Pubitemid 44708207)
54. Diagnostic and statistical manual of mental disorders, 4th edition, text revision. Chap. 55. Washington, DC: American Psychiatric Association; 2000.
55. Kipnis J, Cardon M, Strous RD et al. Loss of autoimmune T cells correlates with brain diseases: possible implications for schizophrenia? Trends Mol Med. 2006; 12:107-12.
56. Chang SH, Chiang SY, Chiu CC et al. Expression of anti-cardiolipin antibodies and inflammatory associated factors in patients with schizophrenia. Psychiatry Res. 2011; 187:341-6.
57. Halacheva K, Dimova S, Tolev T et al. Elevated anticardiolipin antibodies in schizophrenic patients before and during neuroleptic medication. Psychiatry Res. 2009; 169:51-5.
58. Sokol DK, O'Brien RS, Wagenknecht DR et al. Antiphospholipid antibodies in blood and cerebrospinal fluids of patients with psychosis. J Neuroimmunol. 2007; 190:151-6. (Pubitemid 47625611)
59. Shcherbakova IV, Siryachenko TM, Mazaeva NA et al. Leukocyte elastase and autoantibodies to nerve growth factor in the acute phase of schizophrenia and their relationship to symptomatology. World J Biol Psychiatry. 2004; 5:143-8. (Pubitemid 44121708)
60. Sinyakov MS, Kessler B, Karp L et al. Platelet-associated antibodies mediate protective autoimmune response in schizophrenia. Neuropsychobiology. 2003; 48:41-6. (Pubitemid 36928714)
61. Spivak B, Schechtman M, Blumensohn R et al. Blind verification of elevated platelet autoantibodies in serum of schizophrenic patients - part I: young subjects. Neuropsychobiology. 2009; 60:44-8.
62. Spivak B, Schechtman M, Schonherz-Pine Y et al. Blind verification of elevated platelet autoantibodies in serum of schizophrenic patients - part II: adult subjects. Neuropsychobiology. 2009; 60:49-54.
63. Borda T, Gomez R, Berría MI et al. Antibodies against astrocyte M1 and M2 muscarinic cholinoceptor from schizophrenic patients' sera. Glia. 2004; 45:144-54. (Pubitemid 38196991)
64. Tanaka S, Matsunaga H, Kimura M et al. Autoantibodies against four kinds of neurotransmitter receptors in psychiatric disorders. J Neuroimmunol. 2003; 141:155-64. (Pubitemid 37289009)
65. Chandley MJ, Miller MN, Kwasigroch CN et al. Increased antibodies for the alpha7 subunit of the nicotinic receptor in schizophrenia. Schizophr Res. 2009; 109:98-101.
66. Gallowitsch-Puerta M, Tracey KJ. Immunologic role of the cholinergic anti-inflammatory pathway and the nicotinic acetylcholine alpha 7 receptor. Ann N Y Acad Sci. 2005; 1062:209-19.
67. Gejman PV, Sanders AR, Duan J. The role of genetics in the etiology of schizophrenia. Psychiatr Clin North Am. 2010; 33:35-66.
68. Handel AE, Ramagopalan SV. The potential role of major histocompatibility complex class I in schizophrenia. Biol Psychiatry. 2010; 68:e29-30; author reply e31.
69. Schwarz MJ, Kronig H, Riedel M et al. IL-2 and IL-4 polymorphisms as candidate genes in schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2006; 256:72-6.
70. Lencz T, Morgan TV, Athanasiou M et al. Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia. Mol Psychiatry. 2007; 12:572-80. (Pubitemid 46816774)
71. Yum SY, Yum SK, Kim T et al. Clinical perspectives on autoimmune processes in schizophrenia. Psychiatr Clin North Am. 2009; 32:795-808.
72. Ganzinelli S, Borda T, Sterin-Borda L. Regulation of m1 muscarinic receptors and nNOS mRNA levels by autoantibodies from schizophrenic patients. Neuropharmacology. 2006; 50:362-71. (Pubitemid 43184364)
73. Margutti P, Delunardo F, Ortona E. Autoantibodies associated with psychiatric disorders. Curr Neurovasc Res. 2006; 3:149-57. (Pubitemid 43764790)
74. Jaaro-Peled H, Ayhan Y, Pletnikov MV et al. Review of pathological hallmarks of schizophrenia: comparison of genetic models with patients and nongenetic models. Schizophr Bull. 2010; 36:301-13.
75. Karayiorgou M, Simon TJ, Gogos JA. 22q11.2 microdeletions: linking DNA structural variation to brain dysfunction and schizophrenia. Nat Rev Neurosci. 2010; 11:402-16.
76. Mikkelsen JD, Thomsen MS, Hansen HH et al. Use of biomarkers in the discovery of novel anti-schizophrenia drugs. Drug Discov Today. 2010; 15:137-41.
77. Mitchell PB, Meiser B, Wilde A et al. Predictive and diagnostic genetic testing in psychiatry. Psychiatr Clin North Am. 2010; 33:225-43.
78. Bale TL. Neuroendocrine and immune influences on the CNS: it's a matter of sex. Neuron. 2009; 64:13-6.
79. Ashdown H, Dumont Y, Ng M et al. The role of cytokines in mediating effects of prenatal infection on the fetus: implications for schizophrenia. Mol Psychiatry. 2006; 11:47-55. (Pubitemid 43251087)
80. Bechter K, Reiber H, Herzog S et al. Cerebrospinal fluid analysis in affective and schizophrenic spectrum disorders: identification of subgroups with immune responses and blood-CSF barrier dysfunction. J Psychiatr Res. 2010; 44:321-30.
81. Heath RG, Krupp IM. Schizophrenia as an immunologic disorder. I. Demonstration of antibrain globulins by fluorescent antibody techniques. Arch Gen Psychiatry. 1967; 16:1-9.
82. Davidson M. Risk of cardiovascular disease and sudden death in schizophrenia. J Clin Psychiatry. 2002; 63(suppl 9):5-11.
83. Baskak SC, Ozsan H, Baskak B et al. [Peripheral blood T-lymphocyte and T-lymphocyte subset ratios before and after treatment in schizophrenia patients not taking antipsychotic medication.] Turk Psikiyatri Derg. 2008; 19:5-12. In Turkish.
84. De Keyser J, Mostert JP, Koch MW. Dysfunctional astrocytes as key players in the pathogenesis of central nervous system disorders. J Neurol Sci. 2008; 267:3-16. (Pubitemid 351248899)
85. Mayilyan KR, Arnold JN, Presanis JS et al. Increased complement classical and mannan-binding lectin pathway activities in schizophrenia. Neurosci Lett. 2006; 404:336-41. (Pubitemid 44108442)
86. Mayilyan KR, Dodds AW, Boyajyan AS et al. Complement C4B protein in schizophrenia. World J Biol Psychiatry. 2008; 9:225-30.
87. Singh B, Bera NK, Nayak CR et al. Decreased serum levels of interleukin-2 and interleukin-6 in Indian Bengalee schizophrenic patients. Cytokine. 2009; 47:1-5.
88. Herberth M, Schwarz E, Bahn S. Problems and promise of immunological factors as biomarkers for schizophrenia. Biomarkers Med. 2008; 2:385-95.
89. Ilani T, Strous RD, Fuchs S. Dopaminergic regulation of immune cells via D3 dopamine receptor: a pathway mediated by activated T cells. FASEB J. 2004; 18:1600-2. (Pubitemid 39561646)
90. Bennett H. Infection, inflammation, and mental illness. The body's immune response to infectious agents may imperil the brain. Harv Ment Health Lett. 2009; 26:1-3.
91. Salleh Mohd R. Life event, stress and illness. MJMS. 2008; 15:9-18.
92. Walder DJ, Walker EF, Lewine RJ. Cognitive functioning, cortisol release, and symptom severity in patients with schizophrenia. Biol Psychiatry. 2000; 48:1121-32. (Pubitemid 32008436)
93. Chakraborti AK, Garg SK, Kumar R et al. Progress in COX-2 inhibitors: a journey so far. Curr Med Chem. 2010; 17:1563-93.
94. Adams DD, Knight JG, Manning P et al. An informative case of Graves' disease with implications for schizophrenia. J Clin Lab Immunol. 2004; 53:13-25.
95. Hebb AL, Robertson HA. PDEs as drug targets for CNS immune disorders. Curr Opin Investig Drugs. 2008; 9:744-53. (Pubitemid 351950871)
96. Olincy A, Stevens KE. Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men. Biochem Pharmacol. 2007; 74:1192-201. (Pubitemid 47417932)
97. Tiligada E, Zampeli E, Sander K et al. Histamine H3 and H4 receptors as novel drug targets. Expert Opin Investig Drugs. 2009; 18:1519-31.
98. Akhondzadeh S, Tabatabaee M, Amini H et al. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr Res. 2007; 90:179-85. (Pubitemid 46177578)
99. Knight JG, Menkes DB, Highton J et al. Rationale for a trial of immunosuppressive therapy in acute schizophrenia. Mol Psychiatry. 2007; 12:424-31. (Pubitemid 46652460)
100. Olincy A, Harris JG, Johnson LL et al. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry. 2006; 63:630-8. (Pubitemid 43848294)
101. Riedel M, Strassnig M, Schwarz MJ et al. COX-2 inhibitors as adjunctive therapy in schizophrenia: rationale for use and evidence to date. CNS Drugs. 2005; 19:805-19. (Pubitemid 43138335)
102. Skurkovich S, Skurkovich B. Anticytokine therapy, especially anti-interferon-gamma, as a pathogenetic treatment in TH-1 autoimmune diseases. Ann N Y Acad Sci. 2005; 1051:684-700. (Pubitemid 41362796)
103. Zhang XY, Zhou DF, Cao LY et al. Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. J Clin Psychiatry. 2004; 65:940-7.
104. Bilici M, Tekelioǧlu Y, Efendioǧlu S et al. The influence of olanzapine on immune cells in patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2003; 27:483-5.
105. Hinze-Selch D, Becker EW, Stein GM et al. Effects of clozapine on in vitro immune parameters: a longitudinal study in clozapine-treated schizophrenic patients. Neuropsychopharmacology. 1998; 19:114-22. (Pubitemid 28288437)
106. Kowalski J, Blada P, Kucia K et al. Neuroleptics normalize increased release of interleukin-1 beta and tumor necrosis factor-alpha from monocytes in schizophrenia. Schizophr Res. 2001; 50:169-75. (Pubitemid 32595666)
107. Laan W, Smeets H, de Wit NJ et al. Glucocorticosteroids associated with a decreased risk of psychosis. J Clin Psychopharmacol. 2009; 29:288-90.
108. Maes M, Meltzer HY, Bosmans E. Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatr Scand. 1994; 89:346-51. (Pubitemid 24157957)
109. Larsen TK, Melle I, Auestad B et al. Early detection of first-episode psychosis: the effect on 1-year outcome. Schizophr Bull. 2006; 32:758-64. (Pubitemid 44412863)
110. Texas Department of State Health Services. Algorithm for the treatment of schizophrenia. http://bellsouthpwp2.net/d/r/drcook/Lane/TMAP/ TMAP%20Schizophrenia%20Web.pdf (accessed 2011 Jul 11).
111. American Psychiatric Association. Schizophrenia clinical tools treatment algorithm. www.psychiatryonline.com/popup.aspx?aID=46264 (accessed 2011 Jul 11).
112. Gobbi G, Pulvirenti L. Long-term treatment with clozapine in an adult with autistic disorder accompanied by aggressive behaviour. J Psychiatry Neurosci. 2001; 26:340-1. (Pubitemid 32912430)
113. Rapaport MH, Delrahim KK, Bresee CJ et al. Celecoxib augmentation of continuously ill patients with schizophrenia. Biol Psychiatry. 2005; 57:1594-6. (Pubitemid 40805391)
114. Müller N, Riedel M, Scheppach C et al. Beneficial antipsychotic effects of celecoxib add-on therapy compared with risperidone alone in schizophrenia. Am J Psychiatry. 2002; 159:1029-34.
115. Abstracts of the 9th Congress of the German Society for Biological Psychiatry, 12-14 October 2006, Munich, Germany. Eur Arch Psychiatry Clin Neurosci. 2006; 256(suppl 2):ii5-52.
116. Bresee CJ, Delrahim K, Maddux RE et al. The effects of celecoxib augmentation on cytokine levels in schizophrenia. Int J Neuropsychopharmacol. 2006; 9:343-8. (Pubitemid 43780502)
117. Levine J, Gutman J, Feraro R et al. Side effect profile of azathioprine in the treatment of chronic schizophrenic patients. Neuropsychobiology. 1997; 36:172-6. (Pubitemid 27472515)
118. Das UN. Perinatal supplementation of long-chain polyunsaturated fatty acids, immune response and adult diseases. Med Sci Monit. 2004; 10:HY19-25. (Pubitemid 38787618)
119. Das UN. Influence of polyunsaturated fatty acids and their metabolites on stem cell biology. Nutrition. 2011; 27:21-5.
120. Amminger GP, Schäfer MR, Papageorgiou K et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry. 2010; 67:146-54.
121. Piontkewitz Y, Assaf Y, Weiner I. Clozapine administration in adolescence prevents postpubertal emergence of brain structural pathology in an animal model of schizophrenia. Biol Psychiatry. 2009; 66:1038-46.